We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in ...